At a Glance
Zydus Lifesciences (formerly Cadila) is flexing hard this year. Q1 FY26 revenue clocked ₹6,528 Cr (↑18% YoY), while PAT hit ₹1,244 Cr (↑6% YoY). OPM at 33% screams efficiency, and P/E of 20.6 looks like a discount in pharma land. Recent moves? Acquiring Amplitude Surgical (France) for €256M, and snagging a USFDA tentative approval for blockbuster drug Ibrutinib ($2.15B market). ROE at 21% and ROCE at 24% show this is no sleepy generic maker—it’s innovating, expanding, and making shareholders smile (except the -24% 1Y stock drop).
Introduction
Zydus started in 1995 as Cadila’s sibling and now plays in the big pharma league. From a ₹250 Cr turnover then to over ₹23,242 Cr in FY25, it’s been compounding faster than your fixed deposit anxiety. Unlike its peers who stick to generics, Zydus loves dabbling in biosimilars, vaccines, specialty drugs, and wellness products.
Despite the market’s cold shoulder (-24% 1Y), Zydus keeps stacking approvals, buying foreign assets, and maintaining fat margins. This is the pharma equivalent of a Bollywood actor doing both masala movies and critically acclaimed hits.
Business Model (WTF Do They Even Do?)
Zydus is a vertically integrated pharma player with four strong pillars:
- Generics: Bread and butter, with US and India markets leading.
- Specialty & Biologics: High-margin focus area (oncology, immunology).
- Consumer Wellness: Brands like Sugar Free, Nutralite.
- API Manufacturing: Back-end strength for cost control.
Add to this global expansion (US, EU, LATAM) and strong R&D (10% of revenue), and you’ve got a company that isn’t just copying molecules—it’s innovating.
Financials Overview
Q1 FY26 Numbers:
- Revenue: ₹6,528 Cr (↑18% YoY)
- EBITDA: ₹2,126 Cr (OPM 33%)
- PAT: ₹1,244 Cr (↑6% YoY)
- EPS: ₹11.6
For FY25, revenue was ₹23,242 Cr with PAT ₹4,673 Cr
